CompletedPhase 2

Platelet-Rich Plasma Therapy for Patellar Tendinopathy

United States30 participantsStarted 2017-04-25

Plain-language summary

The overall goal of this research is to find an effective treatment for patellar tendinopathy (PT). To achieve this, we will conduct a double-blinded randomized controlled trial to investigate if platelet-rich plasma is effective for treatment. Clinical (pain and function scores) and bio-mechanical (knee strength) measures will be correlated with disease modification changes assessed using conventional and novel quantitative magnetic resonance imaging (MRI) and ultrasound (US) techniques.

Who can participate

Age range

18 Years – 39 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age between 18 and 39 years
. Chronic (\>3 months) PT
. Clinical examination consistent with PT
. MRI or US confirmation of PT
. Pain score of 3 or greater on a 10-point visual analogue scale
. Self-report failure of supervised physical therapy
. Self-report failure of at least 2 of the most common treatment options for PT (e.g. NSAIDs, relative rest, ice and bracing).

Exclusion criteria

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in Measure of Pain Level: VISA-P Score

Timeframe: baseline, 16 weeks, 32 weeks, 52 weeks

Change in Measure of Activity Level: Tegner Activity Level Score

Timeframe: baseline, 16 weeks, 32 weeks, 52 weeks

Change in Visual Analogue Scale (VAS) Pain Score

Timeframe: baseline, 16 weeks, 32 weeks, 52 weeks

Trial details

NCT IDNCT03136965

SponsorUniversity of Wisconsin, Madison

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-08-15

Results submitted2023-08-14

View on ClinicalTrials.gov More Patellar Tendinitis trials

Plain-language summary

Who can participate

Age range

18 Years – 39 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age between 18 and 39 years
. Chronic (\>3 months) PT
. Clinical examination consistent with PT
. MRI or US confirmation of PT
. Pain score of 3 or greater on a 10-point visual analogue scale
. Self-report failure of supervised physical therapy
. Self-report failure of at least 2 of the most common treatment options for PT (e.g. NSAIDs, relative rest, ice and bracing).

Exclusion criteria

What they're measuring

Change in Measure of Pain Level: VISA-P Score

Timeframe: baseline, 16 weeks, 32 weeks, 52 weeks

Change in Measure of Activity Level: Tegner Activity Level Score

Timeframe: baseline, 16 weeks, 32 weeks, 52 weeks

Change in Visual Analogue Scale (VAS) Pain Score

Timeframe: baseline, 16 weeks, 32 weeks, 52 weeks